Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New C$50 venture fund gets Merck a first look at new technologies in Quebec

This article was originally published in Scrip

Executive Summary

Merck launched the Merck Lumira Bioscience Fund on 26 March with C$35 million to support venture capital investment in early stage biotechnology companies based in or considering a move to Quebec, Canada. The investment doesn't buy Merck any first right of refusal to partner with the Quebec startups, but it will get the first look at the early stage companies' technology. To acquire or license intellectual property, Merck will have to make separate arrangements outside of the venture funding contracts.

Advertisement
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

SC016765

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel